BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Jeff Albers as a strategic advisor to the company. Mr. Albers is a seasoned industry leader, with experience building early-stage precision medicine companies into fully integrated commercial organizations delivering targeted medicines to patients. Mr. Albers currently serves as the Chairman of Blueprint Medicines and was previously Chief Executive Officer of Blueprint Medicines from 2014 to 2022.
“We are delighted to welcome Jeff as an advisor,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. “Jeff is an industry veteran with a unique combination of skills relevant to the continued growth of our pipeline and evolution as a company. His broad experience and perspective will be tremendously valuable as we continue to advance our lead programs through clinical development, grow our pipeline and ultimately deliver a suite of next-generation targeted cancer therapies to patients worldwide.”
Jeff Albers brings over 25 years of experience in the biopharmaceutical industry, bringing important new medicines to patients with cancer and rare diseases. He currently serves as board chairman at Blueprint Medicines, MOMA Therapeutics and Pheon Therapeutics, board director at Kymera Therapeutics, and board advisor for Life Sciences Cares. From 2014 to 2022, he served as Chief Executive Officer of Blueprint Medicines, where he transitioned the previously research-stage company through an initial public offering and into a leading precision medicine company with a global, fully integrated business, including two U.S. Food and Drug Administration-approved therapies and a rapidly advancing pipeline. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.
“Scorpion was founded with a vision that really resonates with me: to bring the promise of precision medicine to many more people living with cancer,” said Mr. Albers. “I have seen first-hand the power of exquisitely targeted medicines to deliver improved outcomes – better safety, tolerability, and efficacy – across an array of difficult-to-treat diseases. I look forward to working with the Scorpion management team to advance their efforts.”
About Scorpion Therapeutics
Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.
